1. Home
  2. CAMT vs TGTX Comparison

CAMT vs TGTX Comparison

Compare CAMT & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Camtek Ltd.

CAMT

Camtek Ltd.

HOLD

Current Price

$145.72

Market Cap

7.4B

Sector

Technology

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$55.99

Market Cap

7.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAMT
TGTX
Founded
1987
1993
Country
Israel
United States
Employees
N/A
N/A
Industry
Electronic Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.4B
7.9B
IPO Year
2000
2008

Fundamental Metrics

Financial Performance
Metric
CAMT
TGTX
Price
$145.72
$55.99
Analyst Decision
Buy
Strong Buy
Analyst Count
11
5
Target Price
$158.55
$49.80
AVG Volume (30 Days)
344.4K
1.9M
Earning Date
05-12-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1746.67
EPS
N/A
0.17
Revenue
N/A
$2,785,000.00
Revenue This Year
$14.61
$49.08
Revenue Next Year
$19.36
$26.69
P/E Ratio
$155.63
$337.06
Revenue Growth
N/A
N/A
52 Week Low
$85.38
$26.76
52 Week High
$215.99
$59.30

Technical Indicators

Market Signals
Indicator
CAMT
TGTX
Relative Strength Index (RSI) 43.20 63.39
Support Level $127.66 $51.22
Resistance Level $158.46 $58.04
Average True Range (ATR) 7.13 2.67
MACD -2.11 0.57
Stochastic Oscillator 20.90 88.26

Price Performance

Historical Comparison
CAMT
TGTX

About CAMT Camtek Ltd.

Camtek Ltd is engaged in the manufacturing of metrology and inspection equipment and software solutions for the semiconductor industry. Its systems inspect wafers for various semiconductor market segments, including Advanced Packaging, Chiplets, HBM, Compound Semiconductors, Memory, CMOS Image Sensors, Power, RF and MEMS, serving the industry's IDMs, OSATs, and foundries. Geographically, it derives maximum revenue from China followed by Asia Pacific, Korea, United States, and Europe. The company's products and services include Surface Inspection, Bump Inspection and Metrology, and others.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: